Shares of Salarius Pharmaceuticals SLRX higher in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share increased 77.27% over the past year to ($0.10), which beat the estimate of ($0.11).
Revenue of $1,479,000 higher by 42.35% year over year, which missed the estimate of $1,480,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Mar 18, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/xbt3vxg9
Technicals
52-week high: $3.50
52-week low: $0.56
Price action over last quarter: Up 112.16%
Company Profile
Salarius Pharmaceuticals Inc is a biotechnology company developing targeted therapies to treat pediatric and other cancers, including advanced solid tumors. Its lead compound Seclidemstat is in clinical development for treating Ewing sarcoma.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
